Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) recently presented promising clinical data for its lead candidate, ZN-c3, at the AACR Annual Meeting. The combination of ZN-c3 with chemotherapy showed an objective response rate (ORR) of 30.2% in advanced ovarian cancer patients. Additionally, in patients with uterine serous carcinoma (USC), ZN-c3 achieved a 27.3% ORR and a 90.9% disease control rate with notable tolerability. The results suggest ZN-c3's potential as a significant therapeutic option in treating advanced cancers.
Zentalis Pharmaceuticals has announced promising results from its ongoing Phase 1b trial of ZN-c3, a potential best-in-class Wee1 inhibitor, in combination with chemotherapy for platinum-resistant ovarian cancer. The treatment demonstrated an overall response rate (ORR) of 30.2% across all evaluated chemotherapy cohorts, with the highest cohort reaching 62.5%. ZN-c3 showed good tolerability, exhibiting a better safety profile than other Wee1 inhibitors. The company plans to advance to a Phase 3 trial based on these results.
Zentalis Pharmaceuticals has announced a strategic collaboration with Caris Life Sciences to enhance patient recruitment for its clinical trials. This partnership will utilize Caris’ advanced molecular profiling to identify candidates for Zentalis’ oncology studies, particularly focusing on the Wee1 inhibitor ZN-c3. Both companies aim to leverage comprehensive genomic data to improve therapeutic development. Zentalis retains full ownership of its candidates while pursuing innovative cancer treatments.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the dosing of its first patient in a Phase 1/2 trial for ZN-d5, an oral selective BCL-2 inhibitor, targeting relapsed or refractory light chain (AL) amyloidosis. This trial (ZN-d5-003) aims to evaluate the safety, efficacy, and pharmacokinetics of ZN-d5 in patients with this rare and life-threatening condition. AL amyloidosis affects ~75,000 people globally, causing severe organ damage with limited treatment options. Zentalis aims to provide a potentially best-in-class therapy to address this unmet need.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will present at the Oppenheimer Annual Healthcare Conference on March 16, 2022, at 10:00 a.m. ET. The presentation will be accessible via a live webcast on the company’s website, with an archived version available afterward. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with a promising pipeline including ZN-c3 (Wee1 inhibitor), ZN-c5 (SERD), and ZN-d5 (BCL-2 inhibitor). The company operates from New York and San Diego.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) will present updated data from the Phase 1 expansion cohort of its Wee1 inhibitor ZN-c3 for uterine serous carcinoma (USC) at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. The company highlights five accepted abstracts, including a mini symposium detailing ZN-c3's efficacy and safety. CEO Dr. Anthony Sun expressed optimism about the ongoing trials, noting ZN-c3's promising durability and tolerability. The company aims to explore ZN-c3's potential in combination therapies.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) received Fast Track designation from the FDA for its Wee1 Inhibitor, ZN-c3, targeting uterine serous carcinoma. The company has launched two new trials for ZN-c3 and added a preclinical BCL-xL heterobifunctional degrader candidate to its pipeline. As of December 31, 2021, Zentalis reported $339.9 million in cash and equivalents, which is expected to fund operations into Q3 2023. R&D expenses rose to $175.6 million, indicating intensified clinical pipeline advancements.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a biopharmaceutical firm, announced CEO Anthony Sun's participation in virtual investor conferences. The events include the Guggenheim Oncology Conference on February 10, 2022, at 10:30 a.m. EST, and the SVB Leerink 2022 Global Healthcare Conference on February 17, 2022, at 1:00 p.m. EST. Webcasts will be available on Zentalis's website post-event. The company focuses on developing innovative cancer therapies, including ZN-c3, ZN-c5, ZN-d5, and ZN-e4, targeting various cancer types.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) is hosting a virtual R&D Day on December 16, 2021, from 11:00 a.m. to 12:00 p.m. EST. The event will feature management and three Key Opinion Leaders discussing preclinical science and clinical updates on pipeline candidates, including ZN-d5, an oral BCL-2 inhibitor, and ZN-e4, an oral EGFR inhibitor. Registration is available on their website. Zentalis specializes in developing small molecule therapeutics targeting cancer-related biological pathways.
Zentalis Pharmaceuticals announces the FDA has granted Fast Track designation for its oral WEE1 inhibitor candidate, ZN-c3, aimed at treating recurrent uterine serous carcinoma (USC). This development is significant due to the aggressive nature of USC and its high recurrence rates, underscoring the urgent need for effective therapies. ZN-c3 is currently in a potential registrational Phase 2 trial, with safety updates expected in the second half of 2022. Fast Track designation allows for streamlined communication with the FDA, potentially expediting the approval process.